Fennec Pharmaceuticals In... (FENC)
The price, the headline numbers and the latest news, in one place.
Fennec Pharmaceuticals Inc. Common Stock (FENC) Stock Price, Analysis & Data
| Bid | 8.48 |
| Market Cap | 398.01M |
| Revenue (ttm) | 59.22M |
| Net Income (ttm) | -3.25M |
| 1.07 | |
| -0.11 | |
| n/a | |
| 11.92 | |
| P/B (ttm) | 9.37 |
| P/S (ttm) | 6.72 |
| Earnings Date | Nov 12, 2026 |
| Ask | 14.31 |
| Volume | 246,209 |
| Avg. Volume (20D) | 236,925 |
| Open | 11.79 |
| Previous Close | 11.87 |
| Day's Range | 11.17 - 11.97 |
| 52-Week Range | 5.65 - 13.25 |
| Analyst | n/a |
| Price Target | 16 (40.97%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About FENC
Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of cisplatin-induced ototoxicity pediatric patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. Fennec Pharmaceuticals Inc. has collaboration with Tampa General Hospital Foundation,...
Financial Performance
In 2025, Fennec Pharmaceuticals Common Stock's revenue was 44.64M, a decrease of -6.09% compared to the previous year's 47.54M. Earnings were -9.74M, an increase of 2,134.17%.
Financial StatementsAnalyst Forecast
According to 6 analyst ratings, the average rating for FENC stock is "null". The 12-month stock price forecast is 16, which is upside of 40.97% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
